Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo …
WEB9 hours ago · On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB10 hours ago · Enjaymo reeled in sales of around 100 million euros ($110 million) over 12 months ending in August, Recordati said in its release. The drug is expected to generate revenues in the vicinity of 150 ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB18 hours ago · Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for …
WEB1 day ago · Recordati is paying $825 million up front for global rights to Enjaymo, a drug that is approved in the U.S., Japan, and Europe. If the drug achieves sales milestones, the company could pay out up ...
Recordati buys rights to rare immune disorder drug from Sanofi …
WEB18 hours ago · Recordati said it had signed an agreement for the rights to Enjaymo, a biologic which is the only targeted product for the treatment of CAD approved by the U.S. Food and Drug Administration (FDA ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 …
WEB17 hours ago · Oct 4, 2024 6:47am. By Andrea Figueras. Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 ...
Sanofi’s rare disease drug finds yet another home
WEB9 hours ago · Sanofi is selling global rights to Enjaymo to the Italy-based drugmaker Recordati, in exchange for an upfront payment of $825 million. And if the medicine hits certain sales goals, Sanofi could take home up to $250 million more. For Recordati, which specializes in rare diseases, the deal adds a ninth marketed product to …
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB1 day ago · Recordati will host a conference call today, 4 th October, at 13:00 CEST (12:00 p.m. GMT) to discuss the agreement to acquire Enjaymo®.The dial-in numbers for the conference call service are ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO ...
WEB18 hours ago · Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults ...
Recordati buys rights to rare immune disorder drug from Sanofi …
WEBRecordati shares had jumped 5.3% by 0744 GMT, while Sanofi was up 1.3%. The deal is "very positive" as it will lead to optimised production and an increase in revenues for the Italian firm, a ...
- Some results have been removed